Krsnaa Diagnostics Limited has informed the Exchange about Transcript
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krsnaa Diagnostics filed the transcript of its Q1 FY26 earnings call held on August 12, 2025. The company posted revenue of INR 1,930 million (up 13% YoY), EBITDA of INR 524 million (up 19% YoY) at a 27% margin (a 120 basis point expansion), and profit after tax of INR 205 million (up 15% YoY). Management highlighted the newly won Rajasthan PPP contract, which involves setting up 42 mother labs, 135 satellite labs, and over 1,300 collection centers, requiring INR 200–250 crores in capex and expected to generate INR 300–350 crores in annualized revenue once fully operational in 1.5–2 years. The retail business (RPL) grew sharply, with touchpoints rising from 362 to 2,414 YoY and now contributing 6% of revenue, with a target to reach 18–20% over the next two years. Working capital improved as the company started receiving long-overdue payments from Himachal Pradesh and Karnataka.
Positive for shareholders: margin expansion, strong order win via Rajasthan PPP, and improving working capital signal better days ahead. Near-term stock reaction may be muted as Rajasthan revenue will only flow meaningfully from FY27, but the long-term growth visibility is enhanced.